LONNN Stock Chart & Stats
$11842.56
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$11,700.00 - $13,580.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$783.90B
Enterprise Value$41.89K
Total Cash (Recent Filing)$487.00M
Total Debt (Recent Filing)$4.17B
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Jan 27, 2027EPS Estimate
195.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding70,229,020
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)4.13
Price to Sales (P/S)5.78
P/FCF Ratio-185.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14,807.43Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)378.03
Revenue Forecast (FY)$152.36B
Bulls Say, Bears Say
Bulls Say
Strong Organic Sales GrowthSustained 16% CER organic growth across platforms signals durable end-market demand for outsourced R&D and manufacturing. Broad-based platform strength reduces customer concentration risk and supports multi-year revenue visibility as biotech/pharma outsource complex biologics and novel modalities.
Meaningful Margin ExpansionMaterial and upgraded CORE EBITDA margins reflect improved mix, operating leverage and higher-margin platform recovery. Higher sustainable margins enhance cash generation potential and ROIC, making the manufacturing footprint and technical capabilities more profitable over several years.
Strategic Pure‑play CDMO Focus And Disciplined CapexCompleting the shift to a focused CDMO and monetizing non-core assets clarifies strategy and concentrates capital on high-return biologics and advanced synthesis capacity. Explicit IRR/ROIC thresholds and targeted investments support durable competitive positioning and long-term returns.
Bears Say
Persistent Negative Free Cash FlowChronic negative free cash flow after investments signals that operating cash inflows are strained by heavy capex and working-capital needs. Over time this limits financial flexibility for buybacks, debt reduction or opportunistic M&A unless conversion materially improves.
Rising Leverage And Reduced Balance-sheet FlexibilityAlthough capitalization remains solid, rising leverage and shrinking asset/equity cushions reduce headroom for shocks. If revenue or margins soften, higher leverage constrains maneuverability for large, lumpy manufacturing investments and raises refinancing sensitivity.
High, Lumpy Capex And Timing RiskA mid-to-high-teens CapEx intensity target and multi-year CHF7bn program create execution and timing risk: delayed ramps or scope changes can push out returns, amplify negative FCF periods, and temporarily reduce utilization-driven margins at complex biologics and ADC facilities.
LONNN FAQ
What was Lonza Group’s price range in the past 12 months?
Lonza Group lowest stock price was $11700.00 and its highest was $13580.58 in the past 12 months.
What is Lonza Group’s market cap?
Lonza Group’s market cap is $783.90B.
When is Lonza Group’s upcoming earnings report date?
Lonza Group’s upcoming earnings report date is Jan 27, 2027 which is in 186 days.
How were Lonza Group’s earnings last quarter?
Lonza Group released its earnings results on Jul 22, 2026. The company reported $174.987 earnings per share for the quarter, missing the consensus estimate of $185.087 by -$10.1.
Is Lonza Group overvalued?
According to Wall Street analysts Lonza Group’s price is currently Undervalued.
Does Lonza Group pay dividends?
Lonza Group does not currently pay dividends.
What is Lonza Group’s EPS estimate?
Lonza Group’s EPS estimate is 195.45.
How many shares outstanding does Lonza Group have?
Lonza Group has 70,229,020 shares outstanding.
What happened to Lonza Group’s price movement after its last earnings report?
Lonza Group reported an EPS of $174.987 in its last earnings report, missing expectations of $185.087. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lonza Group?
Currently, no hedge funds are holding shares in MX:LONNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lonza Group
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
LONNN Stock 12 Month Forecast
Average Price Target
$14,807.43